

Human papillomavirus (HPV) genotyping and prognostic value of HPV E4 protein and transcription factors NANOG and SOX11 in atypical p16 patchy squamous epithelium of cervix

Maja Kebe Radulovic¹, Anja Ostrbenk², Mario Poljak², Margareta Strojjan-Flezar¹

¹ Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

² Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Radiol Oncol 2025; 59(3): 391-402.

Received 16 March 2025

Accepted 18 April 2025

Correspondence to: Asist. Maja Kebe Radulović, M.D., Institute of Pathology, Korytkova 2, Ljubljana, Slovenia.

E-mail: maja.kebe-radulovic@mf.uni-lj.si

Disclosure: No potential conflicts of interest were disclosed.

This is an open access article distributed under the terms of the CC-BY license (<https://creativecommons.org/licenses/by/4.0/>).

Background Immunohistochemical staining for p16 is used to differentiate precancerous cervical lesions in tissue samples, but the interpretation of patchy p16 expression remains challenging. We performed human papillomavirus (HPV) genotyping and evaluated the immunohistochemical expression of HPV E4 protein – a marker for transient infections, stem cell transcription factor NANOG, and transcription factor SOX11 to detect possible high-grade squamous lesions in atypical p16 patchy squamous epithelium.

Materials and methods. We analyzed 24 cervical tissue samples with atypical squamous epithelium and patchy p16 expression along with the following controls: 11 cases of atypical squamous epithelium with null p16 expression, 9 condylomas, 12 cases of cervical intraepithelial neoplasia (CIN) grade 1, 11 cases of CIN2, and 9 cases of CIN3. In addition, HPV genotyping of tissue and related cervical smears from up to two years prior to biopsy was performed. Immunohistochemical staining for Ki67, HPV E4, NANOG, and SOX11 was performed and compared with follow-up data.

Results. High-risk HPV infection was detected in 6/24 cases with patchy p16 expression, HPV E4 was expressed in 1/24 cases with patchy p16, weak NANOG expression was found in 11/24 cases with patchy p16 expression while no SOX11 expression was observed. During 10 months of follow-up, one CIN1 and two CIN3 were identified, and another CIN1 and CIN3 after 5 and 6 years, accordingly.

Conclusions. Our study showed that atypical squamous epithelium with patchy p16 expression poses a risk for high-grade precancerous lesions, harbouring high-risk HPV infection. Novel markers may hold diagnostic value in other specific contexts.

Key words: p16; cervical intraepithelial neoplasia; genotype; human papillomavirus; NANOG; SOX11

Introduction

Histopathological diagnosis of precancerous lesions of the cervix is a prerequisite for treatment decisions for asymptomatic women who had cellular abnormalities detected in cervical smears.¹

Following the publication of the Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions (LAST) recommendations, a two-tiered classification system was established for the most common precancerous changes, namely low-grade squamous intraepithelial lesions

(LSIL) and high-grade squamous intraepithelial lesions (HSIL), reflecting the association with human papillomaviruses (HPV).² LSIL is typically associated with productive and transient HPV infections that carry a low risk of progression, whereas HSIL is linked to transforming and persistent HPV infections with a high risk of progression to cancer.³⁻⁶ In light microscopy evaluation of changes with intermediate histomorphological features, previously classified as cervical intraepithelial neoplasia grade 2 (CIN2), it is not always possible to reliably determine whether it is LSIL or HSIL; moreover the histomorphological appearance of CIN2 can overlap with various benign conditions.^{2,5}

To improve the diagnosis of CIN2, the LAST guidelines recommend immunohistochemical staining for cyclin-dependent kinase inhibitor p16 as a surrogate marker for transforming HPV infection.² A strong diffuse immunohistochemical reaction en bloc for p16 is significantly associated with HSIL.² In the foundational literature, positive p16 was not a mandatory criterion for the diagnosis of CIN2, although in longitudinal studies, CIN2 with negative p16 usually regressed.⁶⁻⁸

Recent studies report significant increase in the use of p16 to define these lesions, while also observing a discrepancy between p16 results and histomorphological assessment in more than 30% of CIN2 cases.⁹⁻¹¹ An additional challenge is ensuring the correct interpretation of patchy p16, which may not meet the aforementioned criteria but may be associated with HSIL in a fraction of women.^{9, 11-13}

Several studies have explored the prognostic value of p16 immunostaining in the follow-up of CIN2. In one study, 220 CIN2 cases were analysed and categorized by p16 expression into bloc-positive ($n = 40$), negative ($n = 130$), and ambiguous ($n = 50$) groups.¹¹ During a 12-month follow-up, HSIL was detected in 14 of 40 (35%) bloc-positive cases, 2 of 130 (1.5%) p16-negative cases, and 8 of 50 (16%) ambiguous cases. The ambiguous group was further subclassified into strong/basal, strong/focal, and weak/diffuse patterns, all of which showed similar HPV detection rates (28–35%) and clinical outcomes. In the other studies with the follow-up periods of 12 and 36 months respectively, p16-negative CIN2 lesions consistently demonstrated a high likelihood of regression and no observed progression, while p16-positive CIN2 lesions had a significantly higher risk of progression to CIN3 (10–24%).^{7,8}

Accurate histopathological diagnosis of cervical lesions prevents overtreatment, which can

significantly compromise a woman's fertility, particularly due to premature birth, while insufficient treatment may be associated with progression to cervical cancer.^{14, 15}

The LAST guidelines also mention the use of the proliferation marker Ki67. It is only recommended for ambiguous or technically inadequate reactions with p16 and not routinely, as its sensitivity and specificity are lower compared to p16.^{2, 16, 17}

Expression of the E4 protein of HPV has also been described in previous publications as a potential marker of productive HPV infection, both in the cervix and in skin lesions, anal, and oral mucosa.¹⁸⁻²⁴ Studies have shown that it stains a larger proportion of CIN2 than CIN3.²⁵⁻²⁸ In CIN3, combined lesions with productive and transforming infection predominated.²⁸

A new potential marker for dysplastic changes in squamous epithelium is NANOG, a transcription factor of embryonic stem cells.²⁹ It is mostly not expressed in other normal human tissues in adults, except in the ovary and testis, but is frequently expressed in various types of carcinomas in the head and neck region, lungs, esophagus, stomach, colon, pancreas, liver, bladder, prostate, testicles, and ovaries.²⁹⁻³¹ It is also present in precancerous changes of the squamous epithelium of the head and neck, cervix, and glandular epithelium of the stomach.^{29, 30}

NANOG expression in the cervix is primarily cytoplasmic, with weak positivity observed in some glandular cells of normal tissue, although some studies report its absence, including in the cervical transformation zone.^{30, 32} The findings in thus far limited studies vary; one study showed focal positivity in 30% of CIN1 cases but no positivity in CIN3 cases.³² In invasive squamous cell carcinoma, NANOG expression was heterogeneously positive in 23% of cases, with stromal cell positivity linked to disease progression.³² In another study, increased NANOG expression was found to correlate with the severity of dysplasia, peaking in invasive carcinoma.³³ However, mRNA studies reported no significant differences between CIN2, CIN3, and invasive carcinoma, although expression was lower in negative controls, supported by immunohistochemistry.^{34, 35} In HPV16/18-positive cell cultures, NANOG enhances HPV long control region activity and elevates E6/E7 mRNA levels, while HPV E7 increases NANOG expression in epithelial cells. The NANOG binding sites are specific for high-risk HPV types.^{36, 37}

SOX11, a transcription factor involved in tumor development and immunosuppression, has been

proposed as a marker for dysplastic changes in cervical squamous epithelium, with conflicting results.³⁸ Some studies report significant expression in the basal cells of the normal cervix and in LSIL, while others find SOX11 expression exclusively in squamous cell carcinoma of the cervix, with no expression in normal cervical tissue.^{38, 39, 40}

The aim of this study was to evaluate the potential of the biomarkers HPV E4, NANOG and SOX11 together with HPV genotyping in atypical squamous epithelium with a patchy p16 expression to detect potential cervical precancerous lesions. The expression of biomarkers was compared to a control group consisting of atypical squamous epithelium with negative p16, condylomas, CIN1, CIN2 and CIN3 cases. Follow-up data on precancerous lesions were obtained from the National Cervical Cancer Screening Registry.

Materials and methods

The study protocol was approved by the Medical Ethics Committee of Slovenia (Consent 0120-107/2020/3) on March 17, 2020.

Participants

Cervical tissue samples fixed in 10% buffered formalin and embedded in paraffin, from the archives of the Institute of Pathology, Faculty of Medicine, University of Ljubljana (IP FM UL) were used for this retrospective study. Using the laboratory information system, we identified cases labeled “p16 neg” from gynecological biopsies between January 1, 2016, and December 31, 2018. The study focused on that period because it provided sufficient time for complete follow-up. Of the 320 matches, we excluded glandular changes, LSIL cases, and cases of cervical abrasion.

We selected 20 unequivocally p16-negative i.e. p16 null atypical squamous epithelium cases and 56 with patchy p16 expression. After review, cases with sufficient tissue were retained, 11 p16-negative (null) cases and 24 with patchy nuclear and cytoplasmic positivity (Figure 1).

Atypical squamous epithelium was morphologically classified as such when the proliferating squamous or metaplastic epithelium exhibited nuclear atypia, characterized by enlarged nuclei and irregular nuclear membranes. Cytoplasmic differentiation was minimal or absent in the middle and superficial thirds of the epithelium.




FIGURE 1. Images of atypical squamous epithelium cases with patchy p16 reaction: (A–F). The same sample stained with HE and p16 at 200× magnification. Panels (A), (C), and (E) show HE staining, while panels (B), (D), and (F) show corresponding p16 staining.

The control group included 9 condylomas, 12 CIN1, 11 CIN2, and 9 CIN3, matched for age (± 5 years) with atypical squamous epithelium cases with patchy p16 reaction, diagnosed at IP FM UL between January 1, 2015, and December 31, 2019. All slides in the study were independently reviewed by two pathologists. Eligible tissue samples were identified through our laboratory information system. After the review, samples with adequate material for additional testing were selected. The exclusion criteria specified that no lesions classified as higher grade than the defining group were present in the slides from these women.

The final study group, in which all immunohistochemical (IHC) stainings and HPV genotyping were performed, included 17 excision biopsies and

7 conizations in the group with patchy p16 reaction, 9 excisions and 2 conizations in the group with null p16 reaction, 6 excisions and 3 conizations in the group with condylomas, 5 excisions and 7 conizations in the CIN1 group, 5 excisions and 6 conizations in the CIN2 group and 2 excisions and 7 conizations in the CIN3 group.

HPV genotyping

HPV genotyping was performed at the Institute of Microbiology and Immunology (IMI) FM UL. The samples were prepared according to previously described in-house protocol.⁵ Briefly, we cleaned the microtome with xylene and a DNA decontamination solution before cutting 5 sections of 10 µm from the paraffin block, with first two sections being discarded. A negative control (leiomyoma tissue) was cut between consecutive samples. A new blade was used for each sample. The last tissue section was designated for hematoxylin and eosin staining (HE) to assess the presence of changes in the remaining tissue block. In addition, corresponding cervical smears of the same patients that were taken up to two years before the tissue biopsy were tested as well.

For the DNA isolation, commercially available QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) was used and HPV genotyping was performed utilizing highly sensitive Allplex HPV28 Detection Kit (Seegene, Seoul, South Korea), both following the manufacturer's instructions. The latter enables individual detection of 28 HPV genotypes: HPV6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 66, 68, 69, 70, 73, 82. For further analysis, the latest IARC classification was followed, where the following 12 HPV genotypes were considered as high-risk: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59⁴¹ and the remaining 16 were categorized as low-risk (LrHPV) genotypes.

Immunohistochemical methods

Immunohistochemical analyses for p16, Ki67, E4 HPV, NANOG and SOX11 were conducted on 3–4 µm sections of formalin-fixed, paraffin-embedded tissue. We performed the immunohistochemical reactions which are regularly performed in routine practice without controls, namely Ki67 (monoclonal antibody, clone MIB-1, Dako, Agilent Technologies, Santa Clara, California, USA), p16 (antibody against p16INK4a protein) (clone E6H4, Ventana/Roche), SOX11 (Mouse monoclonal antibody, clone MRQ-58, Cell Marque, Rocklin, California, USA).

Immunohistochemical reactions for E4 HPV were performed using commercially available monoclonal antibodies against E4 (XR-E4-1) (IVD, Labo Bio-medical Products, Rijswijk, Netherlands), which react with the E4 protein from at least the following HPV strains: 6, 11, 16, 18, 27, 31, 33, 35, 39, 42, 43, 44, 45, 51, 52, 53, 56, 57, 58, 59, 66, 67, 70, and 74. Both negative and positive controls were included on each slide. For the negative control, we used leiomyoma tissue, and for the positive control, a case of CIN1.

Immunohistochemical reactions for NANOG were performed using commercially available monoclonal antibodies against NANOG (Cell Signaling, dilution 1:200) (Merck, Kenilworth, New Jersey, USA). One negative and three positive controls were included on each slide. For the negative controls, we used normal endocervical tissue and for the positive controls a non-keratinizing squamous cell carcinoma of the oropharynx, a seminoma of the testis, and CIN3.

The staining process for all immunohistochemical reactions was performed automatically using the BenchMark XT apparatus (Ventana, Tucson, Arizona, USA), with the ultraVIEW detection system and/or OptiVIEW DAB Detection Kit (Roche, Basel, Switzerland).

The criteria for the evaluation were adjusted to the different expressions of the markers. Ki-67 was evaluated as a positive reaction with nuclear staining. Parabasal reaction in the squamous epithelium was considered normal (0); otherwise, it was assessed by thirds of the thickness of squamous epithelium, namely 1 (predominantly lower 1/3), 2 (predominantly lower 2/3), 3 (full thickness).⁴² For p16, a positive tissue reaction was assessed as diffuse, strong staining of cytoplasm and nuclei in at least the lower third of the epithelium (en bloc).² The reaction was evaluated with 3 levels: 0 for completely negative reaction, 1 for reaction with isolated stained nuclei and cytoplasm (patchy), 2 for positive reaction en bloc as described above. For HPVE4, a positive tissue reaction was assessed as cytoplasmic staining of at least one squamous epithelial cell.^{22, 27} For NANOG, a positive reaction was assessed as staining of the cytoplasm or nucleus.^{43, 44} The reaction was evaluated in three levels: 1 for weak reaction stronger than endocervical cells in the control, 2 for moderate reaction similar to CIN3, and 3 for strong reaction as seen in the nuclei of control seminoma cells. SOX11 was evaluated as a positive reaction with nuclear staining of epithelial cells.^{38, 39}

Follow-up

Follow-up data on cytology, HPV testing and tissue biopsy diagnosis from the date of sample collection until May 30, 2024 were obtained from National Cervical Cancer Screening Registry ZORA.⁴⁵

Statistical analysis

Statistical analysis was conducted using IBM SPSS Statistics 27. The Spearman correlation test was applied due to the data's non-parametric nature, with $p < 0.05$ as the significance threshold.

Results

The age of the women included in the study ranged from 20 to 75 years (average 39 years). There was no statistical difference in ages between groups, except between the group with p16 null reaction and the condyloma group ($r = -0.457$, $p = 0.021$), because women in the condyloma group were significantly younger (mean age 33 years) compared to the group with null p16 reaction (mean age 42 years).

The results of immunohistochemical reactions for p16, Ki67, HPVE4, NANOG, and Sox11 with HPV genotyping in cervical tissue biopsies and cervical smears, together with follow-up data are presented in Tables 1-4.

HPV genotyping

For all cases, a moderate correlation between HPV genotypes detected in cervical smears and in histological sample was observed, with a special emphasis that cervical smears were taken up to 2 years prior to tissue biopsy samples ($r = 0.526$, $p = 0.001$). The correlation was statistically significant for hrHPVs ($r = 0.633$, $p = 0.000$) but not significant for lrHPVs ($r = 0.261$, $p = 0.114$).

In squamous epithelial atypia with null p16 expression the following HPVv were detected in tissue as a single infection: 53, 82.

In squamous epithelial atypia with patchy p16 expression the following HPVv were detected in tissue as either single/co-infection: 6, 16, 31, 39, 44, 52, 53, 56, 59, 66, 68, 58, 73.

In condylomas the following HPVv were detected in tissue as either single/co-infection: 6, 11, 16, 18, 44, 51.




FIGURE 2. Only case in the group with atypical squamous epithelium with patchy p16 expression and positive reaction for E4 human papillomavirus (HPV). The tissue was positive for HPV16 and 31 and the follow-up was negative. The same section at 100x magnification: (A) HE staining; (B) p16 staining, (C) Ki67 staining, (D) E4 HPV staining, (E) Nanog staining, F. SOX11 staining.

In CIN1, the following HPVv were detected in tissue as either single/co-infection: 6, 16, 31, 40, 51, 52, 53, 56, 61, 66, 68, 70.

In CIN2, the following HPVv were detected in tissue as single infections: 16, 31, 58, 73, while co-infections included 18 and 58, 26 and 53, and 58 and 59.

In CIN3, the following HPVv were detected in tissue as single infections: 16, 18, 31, 51, while co-infections included 16 and 52.

Regarding various hrHPVs, HPV16, either single or as a coinfection, was present in none of the cases from the group with a completely negative reaction to p16, in 1 case from the group with a patchy reaction to p16, in 2 cases in the CIN1 group and the condyloma group, in 2 cases in the CIN2 group, and in 4 cases in the CIN3 group.

E4 HPV

E4 HPV was more frequently expressed in thickened epithelium with hyper- and parakeratosis of




FIGURE 3. One of the three cases in the group with atypical squamous epithelium with patchy p16 with CIN3 on follow-up. The tissue was positive for human papillomavirus (HPV) 52, 53, 56, 66, 73. The same section at 100x magnification: (A) HE. (B) p16 staining. (C) Ki67 staining. (D) E4 HPV staining. (E) NANOG staining. (F) SOX11 staining.

CIN1 and CIN2 than in other groups, including the majority of atypical squamous epithelia with patchy or null p16 expression.

E4 HPV was negative in all cases with negative tissue HPV genotyping and all 7 cases with confirmed single HPV6 infection, including five condyloma cases, one CIN1 case and one case in the patchy p16 group.

In the atypical squamous epithelium with patchy p16 expression group was an exception a case with positive E4 HPV and with HPV16 and 31, where NANOG was 1+ and Ki67 was expressed throughout the epithelium. (Figure 2).

Another exception were two cases of negative E4 HPV in the CIN1 group, namely one conization

case with HPV16 detected on genotyping and in another biopsy case with HPV6 infection, where NANOG was 2+ and Ki67 was expressed throughout the epithelium.

In the CIN2 group, three cases were negative for E4 HPV. One was a biopsy positive for HPV73, another was a conization case with negative HPV genotyping, and the third was a conization case with HPV16 infection. All three cases had weak NANOG expression (1+).

In the CIN3 group, E4 HPV was positive in two cases. One case involved a combined (CIN2 and CIN3) lesion with surface koilocytic changes and HPV16, while the other had no koilocytic changes but was positive for HPV31.

NANOG

The reaction to NANOG was predominantly cytoplasmic, perinuclear, and occasionally nuclear. There was a weak (1+) positive reaction to NANOG in morphologically normal squamous epithelium outside the lesion. Normal glandular epithelium was negative for NANOG, as well as the normal metaplastic squamous epithelium. Atypical squamous epithelium with patchy p16 expression showed 1+ NANOG expression in 11 out of 24 cases, while the remaining cases were negative. Among the 11 NANOG-positive cases, 2 were HPV-negative. In contrast, among the 13 NANOG-negative cases, 7 were HPV-negative.

In a minority of CIN cases, NANOG expression was uneven, sometimes present only in the lower layers of dysplastic epithelium.

Considering a reaction of 2+ or greater (strong reaction), NANOG was positive in 9/20 cases of HSIL, in 1/12 cases of CIN1 (the one with HPV16 infection), but no strong reaction was observed in cases with p16 patchy/null atypical squamous epithelium.

SOX11

The immunohistochemical marker SOX11 was not included in the tables because it was negative everywhere except in one case. The only positive reaction for SOX11 was nuclear, in the basal part of CIN3 with HPV16 infection (Figure 4).

Discussion

HPV genotyping

Our study showed that atypical squamous epithelium with patchy p16 expression, which

should be considered negative for HSIL according to the LAST guidelines, do not exclude high-risk HPV infection or HSIL in the follow-up, which is consistent with findings of previous studies.^{11, 23, 46} In particular, one fourth of cases with atypical squamous epithelium with patchy p16 expression had hrHPV, one fourth had lrHPV, to previous studies.¹¹

Our study group consisting of cases with atypical squamous epithelium with patchy p16 expression closely resembles CIN1 and condylomas in p16 expression, with no statistically significant difference in hrHPV positivity between them (Table 4). Notably, lrHPV are significantly more prevalent in CIN1 and condylomas than in atypical squamous epithelium with patchy p16 expression. In comparison, CIN2 had statistically more hrHPV and less lrHPV than atypical squamous epithelium with patchy p16 expression group. Conversely, there is a statistically significant difference between groups of atypical squamous epithelium with patchy p16 compared to atypical squamous epithelium with null expression. The latter contained no hrHPV, indicating a much lower risk for HSIL, in line with another study.¹¹

p16

We observed that patchy p16 staining, besides in the group with atypical squamous epithelium and patchy p16 expression, is frequently seen in LSIL with lrHPV infections. As expected, en bloc p16 staining appeared exclusively in HSIL and two CIN1 cases containing hrHPV (2). The only exception with positive p16 and negative HPV genotyping in tissue was a CIN2 case with initially positive high-risk HPV genotyping in cervical smear a month before our biopsy. The literature suggests that “HPV-negative” CIN may result from false negatives due to rare or latent infections, p53-related oncogenesis, CIN2 regression, or reactive changes mimicking CIN2, beside the technical issues (loss of tissue).^{47, 48}

Our study confirmed that p16 strongly correlates with hrHPV infection, as no cases of completely p16-negative atypia tested positive for hrHPV. Clinically, this suggests that such patients are unlikely to develop high-risk precancerous changes. Notably, none of the CIN1 cases in our study exhibited a completely negative p16 reaction, which aligns with findings from other studies suggesting that p16 is not a surrogate marker for just transformative infection.^{2, 23, 49}




FIGURE 4. Immunohistochemical reactions in the only cervical intraepithelial neoplasia 3 (CIN3) case with a positive SOX11 reaction in study. The same section at 100x magnification: (A) HE. (B) p16 staining. (C) Ki67 staining. (D) E4 HPV staining. (E) NANOG staining. (F) SOX11 staining.

Ki67

In the group with atypical squamous epithelium and patchy p16 expression, Ki67 showed full-thickness positivity in two of three cases that progressed to CIN3 during follow-up, making it the most reliable predictive marker for future HSIL in this group, consistent with the literature^{8, 50}. However, Ki67 alone would not be sufficient for risk stratification, as there is no clear distinction in its expression between groups with atypical squamous epithelium with patchy versus null p16 expression.

E4 HPV

E4 HPV expression provided the clearest distinction between atypical squamous epithelium with patchy p16 and CIN1/2 groups, being significantly more frequent in CIN1/2 (Table 4). That is in line with another study, where E4 positivity increased with positivity of p16 reaction when p16 expres-

TABLE 1. Immunohistochemical reactions to various biological markers and human papillomavirus (HPV) genotyping in tissue biopsy and previous cervical smear, where available, by study group

Group	p16	N	Ki67	N	E4 HPV	N	NANOG	N	HPV genotyping	N tissue	N smear
p16 null N = 11	Null	11	0	5	Neg.	11	Neg.	7	Neg.	9	3
	Patchy	0	1/3	4	Pos.	0	1	4	IrHPV only	2	1
	En Bloc	0	2/3	0			2	0	hrHPV	0	3
			3/3	2			3	0			
p16 patchy N = 24	Null	0	0	12	Neg.	23	Neg.	13	Neg.	10	2
	Patchy	24	1/3	5	Pos.	1	1	11	IrHPV only	6	2
	En Bloc	0	2/3	3			2	0	hrHPV	8	12
			3/3	4			3	0			
Condyloma N = 9	Null	0	0	0	Neg.	7	Neg.	0	Neg.	0	1
	Patchy	9	1/3	2	Pos.	2	1	9	IrHPV only	6	2
	En Bloc	0	2/3	1			2	0	hrHPV	3	1
			3/3	6			3	0			
CIN1 N = 12	Null	0	0	2	Neg.	2	Neg.	0	Neg.	0	0
	Patchy	10	1/3	2	Pos.	10	1	12	IrHPV only	6	1
	En Bloc	2	2/3	4			2	0	hrHPV	6	3
			3/3	4			3	0			
CIN2 N = 11	Null	0	0	0	Neg.	3	Neg.	0	Neg.	1	0
	Patchy	0	1/3	0	Pos.	8	1	7	IrHPV only	2	0
	En Bloc	11	2/3	2			2	4	hrHPV	8	3
			3/3	9			3	0			
CIN3 N = 9	Null	0	0	0	Neg.	7	Neg.	1	Neg.	0	0
	Patchy	0	1/3	0	Pos.	2	1	3	IrHPV only	0	0
	En Bloc	9	2/3	0			2	3	hrHPV	9	4
			3/3	9			3	2			

0 = null or parabasal reaction of Ki67; 1/3 = Ki67 positive in predominantly lower 1/3 of epithelium; 2/3 = Ki67 positive in predominantly lower 2/3 of epithelium; 3/3 = Ki67 positive in full thickness of epithelium; CIN = cervical intraepithelial neoplasia; hrHPV = high risk HPV; IrHPV = low risk HPV; Neg. = negative reaction; Pos. = positive reaction

sion was limited to the lower two third of the epithelium, since two cases from CIN1 group were p16 positive (Table 1).²³ In the CIN3 group, E4 HPV was positive in one conventional CIN3 case and another with combined lesions.^{23, 50}

As a potential marker of productive HPV infection, E4 HPV was detected in only one case of squamous condyloma. This may not indicate a lack of productive HPV infection but rather that

immunohistochemical staining for E4 HPV does not detect lesional cells related to HPV6, a common cause of condylomas.²⁶ Notably, recent literature and manufacturer specifications no longer mention that this staining is unvalidated for HPV6, suggesting a need for reevaluation.²¹ Among other unvalidated HPV types in single infections, immunohistochemical staining reacted with HPV68-related lesion (one CIN2 case) but not with HPV73

TABLE 2. Follow-up histology, cytology, human papillomavirus (HPV) result by study groups (p16 null and p16 patchy)

Group	Follow up histo	N	Follow up cyto	N	Follow up HPV	N
p16 null (11 cases, 9 biopsies)	Neg	0	Neg	5	Neg	5
	CIN1	1	ASC-US	4	Pos	3
	CIN2	1	LSIL	0		
	CIN3	1	HSIL	0		
p16 patchy (24 cases, 17 biopsies)	Neg	0	Neg	5	Neg	4
	CIN1	2	ASC-US	6	Pos	5
	CIN2	0	LSIL	4		
	CIN3	3	HSIL	2		

ASC-US = atypical squamous cells of undetermined significance; CIN = cervical intraepithelial neoplasia; Follow up cyto = cervical smears from follow-up; Follow up histo = histological samples from follow-up; Follow-up HPV = HPV results using the Hybrid Capture II assay; HSIL = high-grade squamous intraepithelial lesions; LSIL = low-grade squamous intraepithelial lesions; Neg = negative; Pos = positive

Follow-up after radical resections (conizations, cervical amputations, hysterectomies) was not informative, as the lesion was completely removed; therefore, this data is not included. In the case of multiple consecutive examinations (cytology, HPV testing), we only considered the most pathological cytology results or the positive HPV test.

TABLE 3. Biomarkers in the primary biopsy and follow-up in the groups with atypical squamous epithelium with a patchy and a null reaction to p16

Group	Case	Ki67	E4 HPV	Nanog	HPV genotypes	Follow-up sample	Follow-up diagnosis	Time from primary biopsy to follow-up sample
p16	1	1/3	-	1+	31, 52	biopsy	CIN1	2 years
null	2	3/3	-	-	53	biopsy	CIN2	2 years
	3	1/3	-	-	-	biopsy	CIN3	4 months
p16 patchy	4	0	-	-	39	cone	CIN1	8 months
	5	1/3	-	-	-	cone	CIN1	6 years
	6	3/3	-	1+	53	cone	CIN3	5 years
	7	3/3	-	-	52, 53, 56, 66, 73	Cervical amputation	CIN3	10 months
	8	1/3	-	-	44	cone	CIN3	10 months

0 = null or parabasal reaction of Ki67; 1/3 = Ki67 positive in predominantly lower 1/3 of epithelium; 2/3 = Ki67 positive in predominantly lower 2/3 of epithelium; 3/3 = Ki67 positive in full thickness of epithelium; - = negative reaction, + = positive reaction; CIN = cervical intraepithelial neoplasia; HPV = human papillomavirus

(one CIN2 case). This selective reaction may complicate the clinical management E4 HPV negative CIN2, as an undetected hrHPV73 along with an en bloc p16 reaction could be mistaken for a transforming infection, leading to overtreatment.

NANOG

NANOG expression was less frequently observed in atypical squamous epithelium with null or patchy p16 expression compared to normal squamous epithelium, where it typically exhibited a weak 1+ staining pattern. Notably, squamous

metaplastic and glandular epithelium demonstrated a completely negative reactions to NANOG, consistent with findings from previous studies.^{30, 32} This observation supports the final histopathological diagnoses of immature or reactive squamous metaplasia in these lesions at least at some cases with patchy p16 staining.


No strong (2+) NANOG reaction was observed in the group with atypical squamous epithelium and was present in only one case within the LSIL group. This suggests a lower malignant potential in these lesions compared to HSIL. Similar findings have been reported in laryngeal dysplasia, where

TABLE 4. Comparison of different biological markers between groups using Spearman correlation

Groups	p16	Ki67	HPV E4	Nanog	lrHPV tissue	hrHPV tissue	hrHPV: tissue+smear	lrHPV: tissue+smear
p16 null vs. p16 patchy	r = 1 p = 0.000	r = 0.000	r = 0.116	r = 0.089	r = 0.209	r = 0.384 p = 0.025	r = 0.274	r = 0.285
p16 patchy vs. condyloma	r = 0.000	r = 0.535 p = 0.001	r = 0.280	r = 0.494 p = 0.004	r = 0.458 p = 0.007	r = 0.000	r = -0.186	r = 0.494 p = 0.004
p16 patchy vs. CIN1	r = 0.343 p = 0.041	r = 0.35 p = 0.037	r = 0.81 p = 0.000	r = 0.532 p = 0.001	r = 0.354 p = 0.034	r = 0.161	r = -0.039	r = 0.359 p = 0.032
p16 patchy vs. CIN2	r = 1 p = 0.000	r = 0.66 p = 0.000	r = 0.728 p = 0.000	r = 0.632 p = 0.000	r = -0.193	r = 0.45 p = 0.007	r = 0.176	r = -0.089
p16 patchy vs. CIN3	r = 1 p = 0.000	r = 0.683 p = 0.000	r = 0.280	r = 0.575 p = 0.000	r = -0.375 p = 0.032	r = 0.594 p = 0.000	r = 0.433 p = 0.012	r = -0.433 p = 0.012
p16 null vs. condyloma	r = 1	r = 0.617 p = 0.004	r = 0.369	r = 0.664 p = 0.001	r = 0.704 p = 0.001	r = 0.464 p = 0.039	r = 0.066	r = 0.818 p = 0.000
p16 null vs. CIN1	r = 0.963 p = 0.000	r = 0.394	r = 0.84 p = 0.000	r = 0.691 p = 0.000	r = 0.568 p = 0.005	r = 0.569 p = 0.005	r = 0.233	r = 0.652 p = 0.001
p16 null vs. CIN2	r = 1	r = 0.735 p = 0.000	r = 0.756 p = 0.000	r = 0.728 p = 0.000	r = 0.000	r = 0.832 p = 0.000	r = 0.455 p = 0.034	r = 0.204
p16 null vs. CIN3	r = 1	r = 0.783 p = 0.000	r = 0.369	r = 0.665 p = 0.001	r = -0.302	r = 1	r = 0.739 p = 0.000	r = -0.302
Atypia (p16 patchy and null) vs. CIN2	r = 0.811 p = 0.000	r = 0.607 p = 0.000	r = 0.751 p = 0.000	r = 0.598 p = 0.000	r = -0.125	r = 0.521 p = 0.000	r = 0.231	r = -0.007

Bold font = statistically significant correlation; CIN = cervical intraepithelial neoplasia; hrHPV: tissue = high risk HPV detected in tissue; hrHPV: tissue+smear = high risk HPV detected in tissue or in cervical smear taken before biopsy; HPV = human papillomavirus; lrHPV: tissue = low risk HPV detected in tissue; lrHPV: tissue+smear = low risk HPV detected in tissue or in cervical smear taken before biopsy; p = p value; p16 null = atypical squamous epithelium with a null p16 expression; p16 patchy = atypical squamous epithelium with a patchy p16 expression; r = correlation coefficient

Colour scale based on correlation coefficient value:



a strong cytoplasmic NANOG reaction was identified as an independent predictor of carcinoma, whereas weak reactions were not.²⁹ Additionally, the same study noted “negligible” NANOG staining in normal laryngeal squamous epithelium.²⁹ Potential explanations for the negligible NANOG expression in laryngeal epithelium compared to the consistently weak reactions observed in cervical epithelium include selective NANOG binding to hrHPV, though this does not fully explain its presence in not HPV related laryngeal dysplasia.³⁶ We hypothesize that the absence of NANOG expression in squamous metaplastic and glandular epithelium may be just a characteristic of the original glandular epithelium, from which metaplastic squamous epithelium arises.

SOX11

In our study, SOX11 expression in basal cells of the normal cervix, atypical squamous epithelium and LSIL was null, contrary to the literature.³⁸ SOX11 was expressed in one case of CIN3 (Figure 4). Previous studies reported increased SOX11 expression in cervical squamous cell carcinoma and adenocarcinoma.⁴⁰ Despite deeper tissue sectioning, no local invasion was observed in our case, leaving SOX11 expression in the group of HSIL.

Follow-up

During follow-up, three incident cases of CIN3 were identified in the group of atypical squamous epithelium with patchy p16 expression in the initial biopsy. None of these three cases had expressed E4 HPV. All three had confirmed HPV infections, two with lrHPV and one with hrHPV. In contrast, one case in the group of atypical squamous epithelium with patchy p16 expression did express E4 HPV and had a hrHPV, and no precancerous changes were found upon further monitoring (Figure 2). These results support the hypothesis that E4 HPV may be an indicator of productive infection that could regress in the group with patchy p16 expression.

The main limitation of our study is small sample size. Thus, caution is needed in interpreting the results of our study. This underscores the need for additional studies with larger sample size, some of which are already in progress.²⁵

Conclusions

Atypical squamous epithelium with patchy p16 expression, which is considered negative for HSIL according to the LAST guidelines, does not rule out the presence of hrHPV infection or the pos-

sible development of HSIL in the follow-up. None of the CIN3 cases from atypical squamous epithelium with patchy p16 expression group identified during follow-up exhibited E4 HPV expression in the initial biopsy. All three cases had confirmed HPV infections—two with hrHPV and one hrHPV. In contrast, one case in this group that expressed E4 HPV harbored hrHPV but showed no precancerous changes upon further monitoring.

None of the cases with atypical squamous epithelium and patchy p16 expression exhibited strong NANOG reactivity, which was frequently observed in HSIL. Conversely, many cases in this group showed a completely negative NANOG reaction, similar to that seen in normal epithelium with squamous metaplasia.

No hrHPV genotypes were detected in a group of atypical squamous epithelium with null p16 expression, indicating a much lower risk for HSIL. However, this distinction between atypical squamous epithelium with patchy p16 expression and null p16 expression is not yet reflected in clinical guidelines. According to the LAST recommendations, two diagnostic options with different clinical paths exist for atypical squamous epithelium with negative p16 expression. First is that p16-negative HSIL should be interpreted as negative or not associated with HPV pathology, and second that a p16-negative CIN2 should be classified as LSIL. It is possible that patchy p16 expression indicates a tendency toward LSIL, while null p16 expression may suggest a negative result. However, additional test, such as HPV genotyping in the tissue, might be helpful.

Based on our results, we hypothesize that novel markers may hold diagnostic value in specific contexts: E4 HPV for identifying productive HPV infections in CIN1/2, null NANOG expression in atypical squamous epithelium belonging to squamous metaplasia, weak NANOG expression in normal squamous epithelium, strong NANOG expression in high-grade dysplasia and SOX11 for high-grade lesions progressing toward carcinoma. Further studies including larger number of well characterized samples are needed to confirm our findings.

Acknowledgments

This study was funded by the Slovenian Research and Innovation Agency ARIS (research core Fundings No. P3-0054 and P3-0083). M.P. and A.O. are supported by the Horizon 2020

Framework Program for Research and Innovation of the European Commission, through the RISCC Network (funding grant number 847845).

References

1. Ursic-Vrscaj M, Rakar S, Možina A, Kobal B, Takač I, Deisinger I, et al. [Guidelines for management of women with cervical precancerous lesions]. [Slovenian] In: Ursic-Vrscaj M, editor. Ljubljana: Institute of Oncology Ljubljana; 2011. [cited 2025 Feb 27]. Available at: https://zora.onko-i.si/file-admin/user_upload/dokumenti/strokovna_priporocila/2011_Smernice_web.pdf
2. Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. *Arch Pathol Lab Med* 2012; **136**: 1266-97. doi: 10.5858/arpa.LGT200570
3. Klavs I, Učakar V, Oštrbenk A, Jelen M, Poljak M. Prevalenca okužb s človeškimi papilomavirusi (HPV) pri ženskah sodelujočih v Državnem programu zgodnjega odkrivanja predrakavih sprememb materničnega vratu v Sloveniji. In: Ivanuš U, Primic-Žakelj M, editor. *Izobraževalni dan Zora, Zbornik predavanj*. Ljubljana: Onkološki inštitut; 2014. p. 12-21.
4. Fröberg M, Östensson E, Belkić K, Oštrbenk A, Poljak M, Mints M, et al. Impact of the human papillomavirus status on the development of high-grade cervical intraepithelial neoplasia in women negative for intraepithelial lesions or malignancy at the baseline: A 9-year Swedish nested case-control follow-up study. *Cancer* 2019; **125**: 239-48. doi: 10.1002/cncr.31788
5. Gutnik H, Kastelic P, Oštrbenk Valenčak A, Poljak M, Strojman Fležar M. Histomorphologic assessment and distribution of high-risk human papillomavirus (HPV) types in cervical high-grade squamous intraepithelial lesions with unusual histomorphologic features. *Virchows Arch* 2020; **476**: 251-60. doi: 10.1007/s00428-019-02694-7
6. WHO Classification of Tumours Editorial Board. *Female genital tumours*. Lyon: International Agency for Research on Cancer; 2020.
7. Miralpeix E, Genovés J, Solé-Sedeño JM, Mancebo G, Lloveras B, Bellosillo B et al. Usefulness of p16INK4a staining for managing histological high-grade squamous intraepithelial cervical lesions. *Mod Pathol* 2017; **30**: 304-10. doi: 10.1038/modpathol.2016.168
8. Zhang X, Xu Y, Meng T, Shen D. Analysis of factors affecting the prognosis of patients with cervical intraepithelial neoplasia 2. *Oncol Lett* 2020; **20**: 1810-6. doi: 10.3892/ol.2020.11711
9. Maniar KP, Sanchez B, Paintal A, Gursel DB, Nayar R. Role of the Biomarker p16 in Downgrading CIN 2 Diagnoses and Predicting Higher-grade Lesions. *Am J Surg Pathol* 2015; **39**: 1708-18. doi: 10.1097/PAS.0000000000000530
10. Ebisch RMF, Rijstenberg LL, Soltani GG, van der Horst J., Vedder J. E., Hermens M et al. Adjunctive use of p16 immunohistochemistry for optimizing management of CIN lesions in a high-risk human papillomavirus-positive population. *Acta Obstet Gynecol Scand* 2022; **101**:1328-36. doi: 10.1111/aogs.14459
11. Liu Y, Alqatari M, Sultan K, Ye F, Gao D, Sigel K, et al. Using p16 immunohistochemistry to classify morphologic cervical intraepithelial neoplasia 2: correlation of ambiguous staining patterns with HPV subtypes and clinical outcome. *Hum Pathol* 2017; **66**: 144-51. doi: 10.1016/j.humpath.2017.06.002
12. Sun L, Zhang L, Krigman HR, Hagemann IS. p16 Immunohistochemistry is not always required for accurate diagnosis of grade 2 squamous intraepithelial lesions. *J Low Genit Tract Dis* 2018; **22**: 104-9. doi: 10.1097/LGT.0000000000000370
13. Guedes AC, Brenna SM, Coelho SA, Martinez EZ, Syrjänen KJ, Zeferino LC. p16(INK4a) Expression does not predict the outcome of cervical intraepithelial neoplasia grade 2. *Int J Gynecol Cancer* 2007; **17**: 1099-103. doi: 10.1111/j.1525-1438.2007.00899.x
14. Loopik DL, Doucette S, Bekkers RLM, Bentley JR. Regression and progression predictors of CIN2 in women younger than 25 years. *J Low Genit Tract Dis* 2016; **20**: 213-7. doi: 10.1097/LGT.0000000000000218

15. Cokan A, Pakiz M, Sardinšek T, Dovnik A, Kodrič T, Repše Fokter A, et al. Comparison of conservative treatment of cervical intraepithelial lesions with imiquimod with standard excisional technique using LLETZ: A randomized controlled trial. *J Clin Med* 2021; **10**: 5777. doi: 10.3390/jcm10245777
16. Hosseini MS, Talayeh M, Afshar Moghaddam N, Arab M, Farzaneh F, Ashrafganjoei T. Comparison of Ki67 index and P16 expression in different grades of cervical squamous intraepithelial lesions. *Caspian J Intern Med* 2023; **14**: 69-75. doi: 10.22088/cjim.14.1.69
17. Liu J, Su S, Liu Y. The value of Ki67 for the diagnosis of LSIL and the problems of p16 in the diagnosis of HSIL. *Sci Rep* 2022; **12**: 7613. doi: 10.1038/s41598-022-11584-z.
18. Yajid AI, Zakariah MA, Mat Zin AA, Othman NH. Potential Role of E4 Protein in Human Papillomavirus Screening: a Review. *Asian Pac J Cancer Prev* 2017; **18**: 315-319. doi: 10.22034/APJCP.2017.18.2.315.
19. Doorbar J. The E4 protein; structure, function and patterns of expression. *Virology* 2013; **445**: 80-98. doi: 10.1016/j.virol.2013.07.008.
20. Hendawi N, Niklander S, Allsobrook O, Khurram SA, Bolt R, Doorbar J, et al. Human papillomavirus (HPV) can establish productive infection in dysplastic oral mucosa, but HPV status is poorly predicted by histological features and p16 expression. *Histopathology* 2020; **76**: 592-602. doi: 10.1111/his.14019
21. Leeman A, Jenkins D, Marra E, van Zummeren M, Pirog EC, van de Sandt MM, van Eeden A, Schim van der Loeff MF, Doorbar J, de Vries HJC, van Kemenade FJ, Meijer CJLM, Quint WGV. Grading immunohistochemical markers p16INK4a and HPV E4 identifies productive and transforming lesions caused by low- and high-risk HPV within high-grade anal squamous intraepithelial lesions. *Br J Dermatol* 2020; **182**: 1026-1033. doi: 10.1111/bjd.18342
22. Zummeren MV, Kremer WW, Leeman A, Bleeker MCG, Jenkins D, Sandt MV, et al. HPV E4 expression and DNA hypermethylation of CADM1, MAL, and miR124-2 genes in cervical cancer and precursor lesions. *Mod Pathol* 2018; **31**: 1842-1850.
23. Leeman A, Jenkins D, Del Pino M, Ordi J, Torné A, Doorbar J, Meijer CJLM, van Kemenade FJ, Quint WGV. Expression of p16 and HPV E4 on biopsy samples and methylation of FAM19A4 and miR124-2 on cervical cytology samples in the classification of cervical squamous intraepithelial lesions. *Cancer Med* 2020; **9**: 2454-2461. doi: 10.1002/cam4.2855.
24. Doorbar J, Ely S, Sterling J, McLean C, Crawford L. Specific interaction between HPV-16 E1-E4 and cytokeratins results in collapse of the epithelial cell intermediate filament network. *Nature* 1991; **352**: 824-827.
25. Damgaard RK, Jenkins D, de Koning MN, Quint WG, Stoler MH, Doorbar J, et al. Performance of HPV E4 and p16INK4a biomarkers in predicting regression of cervical intraepithelial neoplasia grade 2 (CIN2): protocol for a historical cohort study. *BMJ Open* 2022; **12**: e059593. doi: 10.1136/bmjopen-2021-059593
26. Van Baars R, Griffin H, Wu Z, et al Investigating diagnostic problems of CIN1 and CIN2 associated with high-risk HPV by combining the novel molecular biomarker PanHPVE4 with p16INK4a. *Am J Surg Pathol* 2015; **39**: 1518-28. doi:10.1097/PAS.0000000000000498pmid:http://www.ncbi.nlm.nih.gov/pubmed/26379150
27. Griffin H, Soneji Y, Van Baars R, et al. Stratification of HPV-induced cervical pathology using the virally encoded molecular marker E4 in combination with p16 or MCM. *Mod Pathol* 2015; **28**: 977-93. doi:10.1038/modpathol.2015.52 pmid:http://www.ncbi.nlm.nih.gov/pubmed/2595339
28. Vink FJ, Dick S, Heideman DAM, De Strooper LM., Steenbergen RD, Lissenberg-Witte BI, et al. Classification of high-grade cervical intraepithelial neoplasia by p16INK4a, Ki-67, HPV E4 and FAM19A4/miR124-2 methylation status demonstrates considerable heterogeneity with potential consequences for management. *Int J Cancer* 2021; **149**: 707-16. doi: 10.1002/ijc.33566
29. Rodrigo JP, Villaronga MÁ, Menéndez ST, Hermida-Prado F, Quer M, Vilaseca I, et al. A novel role for Nanog as an early cancer risk marker in patients with laryngeal precancerous lesions. *Sci Rep* 2017; **7**: 11110. doi: 10.1038/s41598-017-11709-9
30. Grubelnik G, Boštjančič E, Pavlič A, Kos M, Zidar N. NANOG expression in human development and carcinogenesis. *Exp Biol Med* 2020; **245**: 456-64. doi: 10.1177/1535370220905560
31. Hu J, Liu J, Chen A, Lyu J, Ai G, Zeng Q, et al. INO80 promotes cervical cancer tumorigenesis by activating Nanog expression. *Oncotarget*. 2016; **7**: 72250-62. doi: 10.18632/oncotarget.12667.
32. Javed S, Sood S, Rai B, Bhattacharyya S, Bagga R, Srinivasan R. ALDH1 and CD133 in invasive cervical carcinoma and their association with the outcome of chemoradiation therapy. *Indian J Med Res* 2021; **154**: 367-74. doi: 10.4103/ijmr.IJMR_709_20
33. Ye F, Zhou C, Cheng Q, Shen J, Chen H. Stem-cell-abundant proteins Nanog, Nucleostemin and Musashi1 are highly expressed in malignant cervical epithelial cells. *BMC Cancer* 2008; **8**: 108. doi: 10.1186/1471-2407-8-108
34. Tulake W, Yuemaier R, Sheng L, Ru M, Lidifu D, Abudula A. Upregulation of stem cell markers ALDH1A1 and OCT4 as potential biomarkers for the early detection of cervical carcinoma. *Oncol Lett* 2018; **16**: 5525-34. doi: 10.3892/ol.2018.9381
35. Han GH, Kim J, Yun H, Cho H, Chung J, Kim JH, et al. CRY1 regulates chemoresistance in association with NANOG by inhibiting apoptosis via STAT3 pathway in patients with cervical cancer. *Cancer Genomics Proteomics* 2021; **18**: 699-713. doi: 10.21873/cgp.2029
36. Díaz-Tejeda Y, Guido-Jiménez MC, López-Carbajal H, Amador-Molina A, Méndez-Martínez R, Gariglio-Vidal P, et al. Nanog, in cooperation with AP1, increases the expression of E6/E7 oncogenes from HPV types 16/18. *Viruses* 2021; **13**: 1482. doi: 10.3390/v13081482
37. Organista-Nava J, Gómez-Gómez Y, Ocádiz-Delgado R, García-Villa E, Bonilla-Delgado J, Lagunas-Martínez A, et al. The HPV16 E7 oncoprotein increases the expression of Oct3/4 and stemness-related genes and augments cell self-renewal. *Virology* 2016; **499**: 230-42. doi: 10.1016/j.virol.2016.09.020
38. Li X, Wu X, Li Y, Cui Y, Tian R, Singh N, et al. Promoter hypermethylation of SOX11 promotes the progression of cervical cancer in vitro and in vivo. *Oncol Rep* 2019; **41**: 2351-60. doi: 10.3892/or.2019.6993
39. Xu S, Dong Y, Huo Z, Yu L, Xue J, Wang G, et al. SOX11: a potentially useful marker in surgical pathology: a systematic analysis of SOX11 expression in epithelial and non-epithelial tumours. *Histopathology* 2019; **74**: 391-405. doi: 10.1111/his.13757
40. Sun Q, Du J, Dong J, Pan S, Jin H, Han X, et al. Systematic investigation of the multifaceted role of SOX11 in cancer. *Cancers* 2022; **14**: 6103. doi: 10.3390/cancers14246103
41. International Agency for Research on Cancer (IARC). Cervical cancer screening. IARC Handbooks of Cancer Prevention. 2022; **18**: 1-456.
42. van Zummeren M, Leeman A, Kremer WW, Bleeker MC., Jenkins D, van de Sandt M, et al. Three-tiered score for Ki-67 and p16INK4a improves accuracy and reproducibility of grading CIN lesions. *J Clin Pathol* 2018; **71**: 981-8. doi: 10.1136/clinpath-2018-205271
43. Grubelnik G, Boštjančič E, Grošelj A, Zidar N. Expression of NANOG and its regulation in oral squamous cell carcinoma. *Biomed Res Int* 2020; **2020**: 8573793. doi: 10.1155/2020/8573793
44. Gu TT, Liu SY, Zheng PS. Cytoplasmic NANOG-positive stromal cells promote human cervical cancer progression. *Am J Pathol* 2012; **181**: 652-61. doi: 10.1016/j.ajpath.2012.04.008
45. ZORA. Slovenian National Cervical Cancer Screening Programme and Registry. Institute of Oncology Ljubljana. [Internet].2005. [cited 2024 Dec 19]. Available at: <https://zora.onko-i.si/en>
46. Castle PE, Adcock R, Cuzick J, Wentzensen N, Torrez-Martinez NE, Torres SM, et al. Relationships of p16 immunohistochemistry and other biomarkers with diagnoses of cervical abnormalities: implications for LAST terminology. *Arch Pathol Lab Med* 2020; **144**: 725-34. doi: 10.5858/arpa.2019-0241-OA
47. Petry KU, Cox JT, Johnson K, Quint W, Ridder R, Sideri M, et al. Evaluating HPV-negative CIN2+ in the ATHENA trial. *Int J Cancer* 2016; **138**: 2932-9. doi: 10.1002/ijc.30032
48. Xing B, Guo J, Sheng Y, Wu G, Zhao Y. Human papillomavirus-negative cervical cancer: a comprehensive review. *Front Oncol* 2021; **10**: 606335. doi: 10.3389/fonc.2020.606335
49. Vink FJ, Dick S, Heideman DAM, De Strooper LMA, Steenbergen RDM, Lissenberg-Witte BI, et al. Classification of high-grade cervical intraepithelial neoplasia by p16INK4a, Ki-67, HPV E4 and FAM19A4/miR124-2 methylation status demonstrates considerable heterogeneity with potential consequences for management. *Int J Cancer* 2021; **149**: 707-16. doi: 10.1002/ijc.33566
50. Kruse AJ, Baak JP, Janssen EA, Kjellvold KH, Fiane B, Lovslett K, et al. Ki67 predicts progression in early CIN: validation of a multivariate progression-risk model. *Cell Oncol* 2004; **26**: 13-20. doi: 10.1155/2004/108305